The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter randomized phase II trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride (GEM) versus GEM in patients with local advanced and metastatic pancreatic cancer.
Y. Sun
No relevant relationships to disclose
Y. Li
No relevant relationships to disclose
S. Qin
No relevant relationships to disclose
D. MA
No relevant relationships to disclose
S. C. Jiao
No relevant relationships to disclose
S. Y. Yu
No relevant relationships to disclose
J. Li
No relevant relationships to disclose
D. Liu
No relevant relationships to disclose
D. Song
Employment or Leadership Position - Zhejiang Kanglaite Pharmaceuticals
D. Li
Employment or Leadership Position - Zhejiang Kanglaite Pharmaceuticals
Stock Ownership - KangLaiTe